ライフサイエンスコーパス: atrial fibrillation

1 vely, for subclinical and clinical new-onset atrial fibrillation).

2 f thromboembolic events-European Registry in Atrial Fibrillation).

3 chial index were among the top predictors of atrial fibrillation.

4 new-onset if there was no prior diagnosis of atrial fibrillation.

5 tors and specific stroke mechanisms, such as atrial fibrillation.

6 ing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation.

7 nting thromboembolic events in patients with atrial fibrillation.

8 ure was associated with an increased risk of atrial fibrillation.

9 trial thromboembolism even in the absence of atrial fibrillation.

10 insights into the trigger and maintenance of atrial fibrillation.

11 hese chronic treatments to all patients with atrial fibrillation.

12 and cardiac atrial disorders independent of atrial fibrillation.

13 revention around the world for patients with atrial fibrillation.

14 of stroke/systemic embolism in patients with atrial fibrillation.

15 tective or harmful in patients with ESRD and atrial fibrillation.

16 ve to warfarin for patients with nonvalvular atrial fibrillation.

17 nticoagulation is underused in patients with atrial fibrillation.

18 the management of patients with nonvalvular atrial fibrillation.

19 myocardial infarction, non-fatal stroke, and atrial fibrillation.

20 veloping cardiac dysrhythmias, most commonly atrial fibrillation.

21 ry heart disease, heart failure, stroke, and atrial fibrillation.

22 major bleeding in patients with nonvalvular atrial fibrillation.

23 mias, such as the long-QT syndrome (LQT) and atrial fibrillation.

24 well as an important substrate of persistent atrial fibrillation.

25 ion, rhythm maintenance, and rate control in atrial fibrillation.

26 = 0.029) were independently associated with atrial fibrillation.

27 easingly used worldwide in the management of atrial fibrillation.

28 roke prevention in patients with nonvalvular atrial fibrillation.

29 vascular disease, stroke, heart failure, and atrial fibrillation.

30 atrial cardiomyopathy given its parallels to atrial fibrillation.

31 limitations, stroke severity, and history of atrial fibrillation.

32 with a history of ischemic heart disease or atrial fibrillation.

33 ith higher rates of device complications and atrial fibrillation.

34 tion is indicated after the first episode of atrial fibrillation.

35 myocardial infarction, non-fatal stroke, or atrial fibrillation.

36 have been associated with increased risk of atrial fibrillation.

37 nsion, thromboembolism, QT prolongation, and atrial fibrillation.

38 patients with both paroxysmal and persistent atrial fibrillation.

39 l; less than 2% of admissions were always in atrial fibrillation.

40 ic drugs for the prevention of nonparoxysmal atrial fibrillation?

41 rant tachycardia (IART) (61.6%), followed by atrial fibrillation (28.8%), and focal atrial tachycardi

42 The prevalence of hypotension (57% vs 48%), atrial fibrillation (50% vs 40%), and other adverse even

43 (23.8%) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (8%) with myocardial infarction,

44 METHODS AND Patients undergoing first atrial fibrillation ablation and postinterventional esop

45 AEF has been reported with all modalities of atrial fibrillation ablation despite esophageal temperat

46 es, are there nevertheless data that support atrial fibrillation ablation in asymptomatic patients?

47 Thus, the only indication for atrial fibrillation ablation in recent guidelines has be

48 AEF complicating atrial fibrillation ablation is associated with a high m

49 DS AND We prospectively studied 33 AT (post- atrial fibrillation ablation or surgical mitral valve re

50 In total, 1802 patients underwent first atrial fibrillation ablation procedure between January 2

51 ion ablation that occurs in 0.1% to 0.25% of atrial fibrillation ablation procedures.

52 eal perforation is a dreaded complication of atrial fibrillation ablation that occurs in 0.1% to 0.25

53 prehensive rhythm control therapy, including atrial fibrillation ablation, and delineate optimum meth

54 Since the original description of atrial fibrillation ablation, numerous studies have demo

55 et chest pain that start days or weeks after atrial fibrillation ablation.

56 l, or cardiac symptoms within 2 months of an atrial fibrillation ablation.

57 asymptomatic esophageal lesions (EDEL) after atrial fibrillation ablation.

58 the most serious and lethal complications of atrial fibrillation ablation.

59 he use of intracardiac electrograms to guide atrial fibrillation (AF) ablation has yielded conflictin

60 trial (LA) fibrosis is a strong predictor of atrial fibrillation (AF) ablation success and has been a

61 rate modification is an emerging strategy in atrial fibrillation (AF) ablation.

62 Atrial fibrillation (AF) affects over 33 million individ

63 od pressure (BP) lowering prevents recurrent atrial fibrillation (AF) after catheter ablation in pati

64 itamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular heart d

65 Atrial fibrillation (AF) and heart failure with reduced

66 Atrial fibrillation (AF) and left ventricular systolic d

67 Atrial fibrillation (AF) and stroke are important major

68 Both obesity and atrial fibrillation (AF) are increasing in epidemic prop

69 isease (CHD) are assumed to be vulnerable to atrial fibrillation (AF) as a result of residual shunts,

70 re known to prevent stroke for patients with atrial fibrillation (AF) but are often underused in comm

71 rease ischemic stroke rates in patients with atrial fibrillation (AF) but increase the risk of bleedi

72 coronary artery evaluation in patients with atrial fibrillation (AF) by using invasive coronary angi

73 Recently published analysis of contemporary atrial fibrillation (AF) cohorts showed an association b

74 The long-term probability of developing atrial fibrillation (AF) considering genetic predisposit

75 rol is challenging in patients with extended atrial fibrillation (AF) duration and persistent/long-st

76 Although atrial fibrillation (AF) guidelines indicate that pharma

77 n College of Cardiology/Heart Rhythm Society atrial fibrillation (AF) guidelines.

78 Atrial fibrillation (AF) has a substantial genetic basis

79 Atrial fibrillation (AF) has been reported as a strong i

80 Catheter ablation (CA) for atrial fibrillation (AF) has emerged as a widespread fir

81 The prevalence of atrial fibrillation (AF) has risen significantly over th

82 Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels

83 uces dose-dependent termination of simulated atrial fibrillation (AF) in the absence of AF-induced el

84 Atrial fibrillation (AF) is a common arrhythmia that pos

85 Atrial fibrillation (AF) is a common arrhythmia.

86 Atrial fibrillation (AF) is a common cardiac disease in

87 Atrial fibrillation (AF) is an all-too-common and often

88 Subclinical atrial fibrillation (AF) is associated with an increased

89 Atrial fibrillation (AF) is common in heart failure (HF)

90 Prevalence of atrial fibrillation (AF) is increasing, due partly to th

91 Asymptomatic atrial fibrillation (AF) is increasingly common in the a

92 Atrial fibrillation (AF) is the most common cardiac arrh

93 Atrial fibrillation (AF) is the most common cardiac arrh

94 Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of an

95 Atrial fibrillation (AF) occurs in many clinical context

96 Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist.

97 ated its role on prognosis in anticoagulated atrial fibrillation (AF) patients and determined whether

98 related to the quality of anticoagulation in atrial fibrillation (AF) patients, reflected by time in

99 and is the leading cause of mortality among atrial fibrillation (AF) patients.

100 rphology has been associated with drivers of atrial fibrillation (AF) risk, including left ventricula

101 kers interact with risk factors to influence atrial fibrillation (AF) risk.

102 and each manifestation of MetS is related to atrial fibrillation (AF) risks.

103 een increasing focus on the rising burden of atrial fibrillation (AF) since the turn of the millenniu

104 ment-binding protein/modulator) is linked to atrial fibrillation (AF) susceptibility in patients.

105 rophic cardiomyopathy patients for new-onset atrial fibrillation (AF) was explored.

106 (OSA) is associated with atrial remodeling, atrial fibrillation (AF), and increased incidence of arr

107 Atrial tachy-arrhytmias, such as atrial fibrillation (AF), are characterised by irregular

108 factor for thromboembolism in patients with atrial fibrillation (AF), but less is known about how di

109 ded variants at >30 loci that associate with atrial fibrillation (AF), including rare coding mutation

110 ate the associations among alcohol abuse and atrial fibrillation (AF), myocardial infarction (MI), an

111 clinical treatment, and clinical outcomes of atrial fibrillation (AF), sustained ventricular arrhythm

112 The heritability of atrial fibrillation (AF), the contribution of genetic an

113 Atrial fibrillation (AF), the most common sustained arrh

114 dial adipose tissue (EAT) is associated with atrial fibrillation (AF), the most frequent cardiac arrh

115 monstrated conflicting mechanisms underlying atrial fibrillation (AF), with the spatial resolution of

116 els constitute a new target for treatment of atrial fibrillation (AF).

117 id valve (TV) may occur secondary to chronic atrial fibrillation (AF).

118 for stroke prevention in most patients with atrial fibrillation (AF).

119 s the cornerstone of ablation for persistent atrial fibrillation (AF).

120 ge and advances in the clinical treatment of atrial fibrillation (AF).

121 ions frequently antecede onset of paroxysmal atrial fibrillation (AF).

122 monly found on brain MRI among patients with atrial fibrillation (AF).

123 ejection fraction in either sinus rhythm or atrial fibrillation (AF).

124 n of the left atrium, potentially leading to atrial fibrillation (AF).

125 short QT syndrome, which is associated with atrial fibrillation (AF).

126 tributors to the self-perpetuating nature of atrial fibrillation (AF).

127 Accumulating evidence links inflammation and atrial fibrillation (AF).

128 c cardiovascular disease (ASCVD) events, and atrial fibrillation (AFib) in a multiethnic cohort.

129 ection (PVR) still determines recurrences of atrial fibrillation after contact force (CF)-guided pulm

130 piration predicts incident heart failure and atrial fibrillation; among patients with heart failure,

131 dies (GWAS) included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wid

132 In this Danish cohort study of patients with atrial fibrillation and a single stroke risk factor, the

133 Patients were included who had atrial fibrillation and an indication for oral anticoagu

134 ibutor to the risk of stroke associated with atrial fibrillation and as a determinant of arrhythmia p

135 of diastolic function and is associated with atrial fibrillation and cardiovascular outcomes.

136 with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin therapy.

137 als with preexcitation had higher hazards of atrial fibrillation and heart failure.

138 natives to warfarin for stroke prevention in atrial fibrillation and management of venous thromboembo

139 subjects and patients and then according to atrial fibrillation and mitral regurgitation status.

140 There were no cases of atrial fibrillation and one case of grade 3 or worse hae

141 s in preventing recurrences of nonparoxysmal atrial fibrillation and reducing hospital admissions.

142 antly present in the EGM recordings only for atrial fibrillation and some atrial flutter propagations

143 eter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI

144 play an important role in the development of atrial fibrillation and that CLICs and structural type I

145 lar benefits were seen in both patients with atrial fibrillation and venous thromboembolism.

146 We identified determinants of new-onset atrial fibrillation and, using propensity matching, char

147 evascularization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocar

148 independent risk factor for both stroke and atrial fibrillation, and in the setting of AF, type 2 di

149 class, use of medications for heart failure, atrial fibrillation, and left ventricular systolic dysfu

150 diomyopathy, cardiac conduction disturbance, atrial fibrillation, and malignant ventricular arrhythmi

151 provide insights into the molecular basis of atrial fibrillation, and may facilitate the identificati

152 tly because of age but also stroke severity, atrial fibrillation, and prestroke functional limitation

153 ed with higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, where

154 nts in organisation of care, knowledge about atrial fibrillation, and treatment options.

155 Epicardial breakthrough waves (EBW) during atrial fibrillation are important elements of the arrhyt

156 ary heart disease, atrial septal defect, and atrial fibrillation are made, and the arrhythmia (atrial

157 ors and fibrosis in patients with persistent atrial fibrillation are mandatory and may inform strateg

158 in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial reported that apix

159 se maps were obtained from 17 simulations of atrial fibrillation, atrial flutter, and focal atrial ta

160 ately doubles the likelihood of freedom from atrial fibrillation, atrial flutter, or atrial tachycard

161 Cspg4 locus led to ventricular arrhythmias, atrial fibrillation, atrioventricular conduction defects

162 -choice therapy in patients with nonvalvular atrial fibrillation because these drugs have several ben

163 risk of short-term mortality, renal failure, atrial fibrillation, bleeding, and length of intensive c

164 outpatient clinics if they had no history of atrial fibrillation but had any of the following: CHA2DS

165 is a recommended treatment for patients with atrial fibrillation, but it is unclear whether it result

166 r rates of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clin

167 ing height is an independent risk factor for atrial fibrillation, but the underlying mechanisms are u

168 ssumptions of this simulation, patients with atrial fibrillation can be triaged to an optimal warfari

169 association study (GWAS) that included 8,180 atrial fibrillation cases and 28,612 controls with follo

170 condary prevention, suffered more often from atrial fibrillation, chronic kidney disease, diabetes me

171 an provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin, with additio

172 Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiodarone, fluco

173 , thrombocytopenia, acute coronary syndrome, atrial fibrillation, congestive heart failure, DM 2, and

174 pathology consultation, anticoagulation for atrial fibrillation, discharge on statin, lipid manageme

175 rteen patients with long-standing persistent atrial fibrillation (duration, 12-72 months) underwent p

176 tes, patients with diabetes also had a lower Atrial Fibrillation Effects on Quality of Life score of

177 ice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391).

178 age) and those with an antecedent history of atrial fibrillation experienced the highest risk of HF a

179 This issue provides a clinical overview of atrial fibrillation, focusing on diagnosis, treatment, a

180 er 2011 to October 2013 with newly diagnosed atrial fibrillation formed the study cohort (65 734 [44.

181 pared with warfarin therapy in patients with atrial fibrillation from the perspective of the US healt

182 n College of Cardiology/Heart Rhythm Society atrial fibrillation guidelines pertaining to antithrombo

183 Radiofrequency catheter ablation for atrial fibrillation has become an important therapy for

184 mic-guided warfarin dosing for patients with atrial fibrillation have demonstrated conflicting result

185 preexcitation had higher adjusted hazards of atrial fibrillation (hazard ratio [HR], 3.12; 95% confid

186 ariants of CAD were linked to development of atrial fibrillation, heart failure, and death.

187 Early diagnosis of atrial fibrillation, ideally before the first complicati

188 n of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recruited from 2

189 the incidence, risk factors, and outcomes of atrial fibrillation in a cohort of critically ill patien

190 rteen genetic loci have been associated with atrial fibrillation in European and Asian ancestry group

191 derlie the development of conditions such as atrial fibrillation in humans.

192 The excess risk of atrial fibrillation in individuals with type 1 diabetes

193 iogram heart rate dynamics detects new-onset atrial fibrillation in many ICU patients.

194 red with the general population, the risk of atrial fibrillation in men with type 1 diabetes was slig

195 t ventricular pacing (RVP) increases risk of atrial fibrillation in patients with implantable cardiov

196 The risk of atrial fibrillation in people with type 1 diabetes incre

197 x new loci were specifically associated with atrial fibrillation in the Japanese population after com

198 To investigate genetic loci associated with atrial fibrillation in the Japanese population, we perfo

199 Over a third of patients with atrial fibrillation in this large outpatient registry re

200 ctivity detection from 60% to 70% of time in atrial fibrillation in unipolar recordings and from 0% t

201 Atrial fibrillation increased with age to surpass IART a

202 Adults with atrial fibrillation initiating dabigatran or warfarin th

203 Atrial fibrillation is a common complication of sepsis a

204 Atrial fibrillation is also a common complication and is

205 Catheter ablation of atrial fibrillation is associated with a risk of cerebra

206 ulmonary vein isolation (PVI) for persistent atrial fibrillation is associated with limited success r

207 sient and frequently unrecognized, new-onset atrial fibrillation is associated with poor hospital out

208 these treatment options to all patients with atrial fibrillation is difficult, despite recent improve

209 coronary artery disease, heart failure, and atrial fibrillation is discussed in detail.

210 ticoagulants among patients with nonvalvular atrial fibrillation is not known.

211 Atrial fibrillation is one of the major cardiovascular h

212 Atrial fibrillation is the most common cardiac arrhythmi

213 cy of catheter-based treatment of persistent atrial fibrillation is unsatisfactory.

214 l fibrillation are made, and the arrhythmia (atrial fibrillation) is indicative diagnosed from health

215 Cardiac disease was defined as a history of atrial fibrillation, ischemic heart diseases, or congest

216 ibrillation (PeAF), long-standing persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibril

217 ly postoperative atrial fibrillation (POAF) (atrial fibrillation </=30 days of surgery), ischemic str

218 ial fibrillation, rotors potentially explain atrial fibrillation maintenance, but their ablation rema

219 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; me

220 Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized 1:1:1 to ad

221 with persistent and long-standing persistent atrial fibrillation, no significant difference was obser

222 ily history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycard

223 d substantially outside the South, including atrial fibrillation (Northwest), aortic aneurysm (Midwes

224 12-lead electrocardiogram without pacing or atrial fibrillation noted on their baseline Jackson Hear

225 atients (1.4%) in the PFO closure group, and atrial fibrillation occurred in 29 patients (6.6%) after

226 and June 2013, a total of 1,087 episodes of atrial fibrillation occurred in 418 (23%) individuals.

227 One serious adverse event (transient atrial fibrillation) occurred in 205 subjects who underw

228 nucleotide polymorphisms was associated with atrial fibrillation (odds ratio=0.89 per SD change; 95%

229 s repeatedly emphasized as a risk factor for atrial fibrillation or flutter (AF).

230 We observed six cases of self-terminating atrial fibrillation or flutter and six cases of partial

231 0- and 360-day complications, and shocks for atrial fibrillation or supraventricular tachycardia.

232 ized clinical trials, enrolled patients with atrial fibrillation or venous thromboembolism, compared

233 n (P = .010); more frequently presented with atrial fibrillation (P < .001), diabetes (P < .001), and

234 t atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial sites are imp

235 oral anticoagulants, more than one third of atrial fibrillation patients still remain untreated.

236 -world" patients if sources drive persistent atrial fibrillation (PeAF), long-standing persistent atr

237 signal intensity in patients with persistent atrial fibrillation (PERS) scheduled for ablation.

238 uring atrial fibrillation, thereby promoting atrial fibrillation persistence.

239 propriately explain long-standing persistent atrial fibrillation physiology at its frequency content.

240 tion of LAA closure with early postoperative atrial fibrillation (POAF) (atrial fibrillation </=30 da

241 However, up to 40% of an atrial fibrillation population may be asymptomatic.

242 double the number of known genetic loci for atrial fibrillation, provide insights into the molecular

243 therapy for ARISTOTLE-eligible patients with atrial fibrillation provides clinical benefits at an inc

244 lying mechanisms sustaining human persistent atrial fibrillation (PsAF) is poorly understood.

245 Robust evidence from patients with atrial fibrillation randomized to NOACs or warfarin demo

246 patients >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs,

247 MIs had a significantly higher prevalence of atrial fibrillation (rate ratio [RR], 1.62; 95% CI, 1.20

248 se maps presented reentrant activity just in atrial fibrillation recordings accounting for approximat

249 were identified as independent correlates of atrial fibrillation recurrence.

250 no difference was observed in terms of free atrial fibrillation-recurrence rates: 79.4% in control v

251 es Registry for Better Informed Treatment of Atrial Fibrillation) registry, a prospective, nationwide

252 s warranted for stroke prevention during non-atrial fibrillation-related cardiac surgery.

253 Once diagnosed, atrial fibrillation requires chronic, multidimensional m

254 e of the PR interval comprises modulators of atrial fibrillation risk and obesity.

255 In human long-standing persistent atrial fibrillation, rotors potentially explain atrial f

256 ction mutations that cause a genetic form of atrial fibrillation, S140G and V141M, drastically slow I

257 tial prevalence of asymptomatic, subclinical atrial fibrillation (SCAF) in patients with pacemakers a

258 ents, prior stroke, diabetes, pacemaker use, atrial fibrillation, slow gait speed, and nonfemoral acc

259 for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using shared clinic

260 infarction, new or worsening heart failure, atrial fibrillation, stroke, deep venous thrombosis, car

261 s moderate-quality evidence that concomitant atrial fibrillation surgery approximately doubles the li

262 dergoing cardiac surgery undergo concomitant atrial fibrillation surgery?

263 may contribute to a better understanding of atrial fibrillation susceptibility and pathogenesis.

264 KCND3 and NEBL genes, which are relevant to atrial fibrillation susceptibility.

265 matic persistent or long-standing persistent atrial fibrillation, the outcomes of initial ablative st

266 ich may enhance the occurrence of EBW during atrial fibrillation, thereby promoting atrial fibrillati

267 oagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarctio

268 ntact Sensing RF Ablation Clinical Trial for Atrial Fibrillation [TRAC-AF]; NCT02821351).

269 in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received >/=1 dose of the

270 A total of 1585 patients with atrial fibrillation undergoing PVI from the Swedish Cath

271 nts (median age, 63.5 years) with persistent atrial fibrillation underwent epicardial thoracoscopic r

272 omatic paroxysmal (n=345; 42%) or persistent atrial fibrillation underwent postprocedural esophageal

273 We found atrial fibrillation using automated detection (>/= 90 s

274 liable prediction of very late recurrence of atrial fibrillation (VLRAF) occuring >12 months after ca

275 New-onset atrial fibrillation was associated with a longer stay (h

276 sted regression analyses, clinical new-onset atrial fibrillation was associated with increased hospit

277 The rate of atrial fibrillation was higher in the PFO closure group

278 New-onset atrial fibrillation was not associated with survival aft

279 als with normoalbuminuria, no excess risk of atrial fibrillation was noted in men with type 1 diabete

280 Most atrial fibrillation was paroxysmal; less than 2% of admi

281 New-onset atrial fibrillation was subclinical or went undocumented

282 es Registry for Better Informed Treatment of Atrial Fibrillation), we determined how frequently patie

283 Georg Hospital for Long-Standing Persistent Atrial Fibrillation), we sought to assess, in patients w

284 herapy for warfarin therapy in patients with atrial fibrillation, we performed a cost-effectiveness a

285 To further define the genetic basis of atrial fibrillation, we performed large-scale, trans-anc

286 Patients with atrial fibrillation were excluded.

287 ND Characteristics from 14 206 patients with atrial fibrillation were integrated into a validated war

288 Cases of atrial fibrillation were obtained from the Swedish Natio

289 spiratory failure, and new-onset subclinical atrial fibrillation, which occurred in 8% of admissions,

290 study included 140 patients with paroxysmal atrial fibrillation, which was refractory to antiarrhyth

291 oring in older patients without a history of atrial fibrillation who are attending outpatient cardiol

292 Question: Should patients with preoperative atrial fibrillation who are undergoing cardiac surgery u

293 nd including 91330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescri

294 g twice daily) and warfarin in patients with atrial fibrillation with 1 low-risk, nonsex-related stro

295 based on stroke prevention for patients with atrial fibrillation with 1 or more stroke risk factors.

296 atched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran

297 ocused on recruiting high-risk patients with atrial fibrillation with more than 2 stroke risk factors

298 To determine the association of new-onset atrial fibrillation with outcomes, including ICU length

299 ing the probability of a first occurrence of atrial fibrillation within the following 24 hours, we pe

300 Atrial fibrillation would have gone undetected in most p